The Latest Breaking News from DaVita

DaVita has surpassed the broader market over the past year, and Wall Street analysts are cautious about the stock’s prospects.

DaVita stock launches a breakout to an all-time high as 44 A+ funds report a position in the kidney care leader.

DaVita is expected to release its fiscal second-quarter earnings next month, and analysts project a double-digit profit increase.

Tandem Diabetes stock rocketed Friday after the insulin pump-maker topped first quarter expectations. But DaVita stock reversed lower.

ResMed stock jumped Thursday after an analyst suggested the growing popularity of weight-loss drugs could drive use of its medical devices.

DaVita stock launched Tuesday after Novo Nordisk unveiled the results of its weight-loss drug in kidney disease patients.

Voters in Colorado could decide on a ballot initiative to adopt top-four ranked-choice voting in Nov. 2024. Kent Thiry, the former CEO of DaVita, said he plans to file the ballot initiative, which would change state executive, state legislative, and congressional elections. The new electoral system would go into effect…

What you need to know… The S&P 500 Index ($SPX ) (SPY ) today is down -0.05%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.04%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.17%. Stocks this morning are slightly lower. The broader market...

The good times keep rolling for Novo Nordisk and its weight-loss drugs. But it's bad news for some medical device stocks.

CEO Javier Rodriguez says it would have been like accepting food stamps when you have a stocked pantry.

A Relative Strength Rating upgrade for DaVita shows improving technical performance.